Brazilian universities have produced remarkable breakthroughs in biotechnology. But sometimes the most revealing part of these stories is not the science itself, it is how the patents were handled. Polylaminin, a promising regenerative biomolecule developed at the Federal University of Rio de Janeiro (UFRJ), illustrates this contrast: while preclinical results suggested significant therapeutic potential, the applications in the United States and Europe were ultimately not maintained through the examination process.
The technology showed promising results in spinal cord injury research and ultimately obtained patent protection in Brazil.
While the Brazilian patent was granted, the corresponding applications in the United States and Europe were abandoned. As a result, a technology protected domestically became commercially open in some of the world’s most important pharmaceutical markets.
For foreign patent attorneys working with biotechnology portfolios, understanding how patent protection works in Brazil, including PCT national phase entries and prosecution before the Brazilian Patent Office (INPI), is essential when developing global IP strategies.
This case offers valuable insights into international filing strategy, prosecution management and cross-border patent coordination.
Understanding the Polylaminin technology
A regenerative Biotechnology breakthrough
Polylaminin is a polymerized form of laminin designed to promote tissue regeneration and reduce inflammation, particularly in traumatic, degenerative or inflammatory injuries. These technical features, including its regenerative and anti‑inflammatory effects in specific tissues such as the spinal cord, brain and lungs, directly inform the scope of the medical use claims later pursued in the Brazilian patent and in the corresponding international filings.
Experimental studies described in the patent documentation demonstrated significant functional recovery in animal models with spinal cord injuries. The invention is based on the discovery that laminin, when polymerized under specific acidic conditions in the presence of divalent cations, exhibits strong regenerative and anti-inflammatory properties.
This innovation opened the door for potential therapeutic applications in regenerative medicine, particularly in the treatment of spinal cord injuries and pulmonary inflammatory conditions.
The Brazilian patent portfolio behind polylaminin
The research surrounding Polylaminin resulted in a small but significant Brazilian patent portfolio associated with researchers at the Federal University of Rio de Janeiro (UFRJ).
Dr. Tatiana Sampaio appears as inventor in three Brazilian patent applications related to protein polymerization and regenerative biotechnology:
• PI 0605212-6: Process for producing dimerized or oligomerized endostatin, dimerized or oligomerized endostatin and pharmaceutical composition (filed in 2006 and granted in 2020)
• PI 0704128-4: Protein polymerization process and polymeric protein and related use (filed in 2007 and lapsed in 2009)
• PI 0805852-0: Use of polymerized laminin in acidic medium to treat traumatic, degenerative or inflammatory tissue lesions (filed in 2008 and granted in 2025)
Among these filings, PI 0805852-0 became the patent most directly associated with the development of Polylaminin as a potential therapeutic technology.
The Use as Medicine Patent
The key Brazilian patent in this case is therefore:
PI 0805852-0: “Use of polymerized laminin in acidic medium to treat traumatic, degenerative or inflammatory tissue lesions.”
This patent focuses on the application of the molecule for using, protecting the use of polymerized laminin in the preparation of pharmaceutical compositions.
The claims cover the use of the compound to treat injuries affecting tissues such as:
• spinal cord
• brain
• lungs
In other words, this patent establishes the medical use concept of the invention.
The manufacturing and production patent
A later filing expanded the protection scope by addressing a key challenge: how to produce the compound reliably.
The subsequent Brazilian patent application BR 102022026276-4 filed by CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA in 2022 describes the industrial processes necessary for extraction, purification and polymerization of laminin, as well as the preparation of polylaminin for therapeutic use.
The patent details:
• extraction methods for laminin derived from human placenta
• purification techniques that preserve the molecule’s polymerization capacity
• processes for acid-mediated polymerization
• a medical preparation kit containing purified laminin and reagents required for immediate preparation of polylaminin.
This second patent contains 51 claims, covering not only the process but also the resulting product and preparation kit. It was published in 2024 and it’s under examination.
While the earlier patent defined what the invention does, the later filing addressed how the molecule can be reliably produced and prepared for clinical use.
In 2023, CRISTÁLIA also filed the PCT/BR2023/050461(titled Laminin Extraction, Purification And Polymerization Processes, Use, Polylaminin And Kit) claiming priority of the above-mentioned patent. National Phases entries were filed in Japan, Israel, India, Mexico, China, EPO and, in Brazil, that received the number BR 112025012354-8 and it is under examination.
Summary
From the early protein polymerization research (PI 0704128-4) to the patent of medicine (PI 0805852-0) and the later manufacturing processes (BR 102022026276-4 and BR 112025012354-8), the portfolio illustrates how academic biotechnology research gradually evolves from scientific discovery into scalable therapeutic technology.
The International Patent Filing Strategy of PI 0805852-0
The Brazilian Filing
The Brazilian patent application was filed in September 2008.
Within the priority period, the applicant filed a PCT application (PCT/BR2009/000051) in February 2009, allowing additional time to determine where international protection should be pursued.
For many universities and research institutions, this step is crucial because it provides time to assess commercial interest before committing to expensive foreign filings.
National Phase Entry in the United States and Europe
Following the PCT procedure, the applicant entered the national phase in two major jurisdictions in 2011:
• the United States Patent and Trademark Office (USPTO)
• the European Patent Office (EPO)
These jurisdictions represent some of the most important markets for biotechnology innovation.
However, the prosecution processes did not continue as expected.
Why the US and European patents were abandoned
The international applications failed during prosecution.
In the United States, the application was abandoned in August 2014 due to failure to respond to an Office Action issued by the USPTO.
In Europe, the application was withdrawn in April 2015 after the applicant failed to respond to examination requirements and did not pay the sixth renewal fee.
Once these applications were abandoned, the opportunity to obtain patent protection in those jurisdictions was effectively lost.
Once the Brazilian application was published, the invention became prior art for subsequent filings abroad, illustrating how international patent strategy often depends as much on prosecution management as on the underlying science.
A structural challenge in Brazilian Biotechnology innovation
The Polylaminin case also highlights a broader structural issue.
In the broader Brazilian biotechnology landscape, this is not an isolated case. Recent data from the Brazilian Patent Office (INPI) indicate that foreign applicants account for roughly 86% of biotechnology patent filings in Brazil, while only about 8–12% of Brazilian biotech inventions are extended abroad, highlighting a persistent asymmetry in the internationalization of local research. The Polylaminin case therefore operates not only as a singular narrative, but also as a concrete example of how promising domestic technologies can remain protected locally yet commercially open in major global markets.
In many cases, limited funding, administrative constraints or shifting institutional priorities can affect the ability to maintain international patent filings. Similar challenges are frequently observed in academic research environments worldwide, particularly when long-term patent prosecution must compete with changing research funding cycles.
Lessons for Foreign Patent Attorneys managing biotechnology portfolios
For patent attorneys and IP professionals working with biotechnology innovations, this case offers several practical lessons.
International prosecution requires continuous management
Filing a PCT application is only the beginning of the process. Maintaining protection across multiple jurisdictions requires careful monitoring of deadlines, office actions and renewal fees.
Budget planning must consider long-term prosecution
Biotechnology patents often involve complex examination procedures and multiple rounds of prosecution.
Without proper planning, applicants may struggle to maintain filings in key jurisdictions.
Cross-border coordination is critical
International patent portfolios require coordination between inventors, institutions and foreign patent attorneys.
Effective communication between jurisdictions can be decisive in preserving global protection.
Why Brazil remains a key Jurisdiction for Biotechnology Patents
Despite the challenges illustrated by this case, Brazil remains an important jurisdiction for biotechnology innovation.
The country offers:
• one of the largest healthcare markets in Latin America
• a strong university research ecosystem
• a growing biotechnology sector.
For global patent strategies, Brazil often plays a key role in life sciences patent portfolios.
Understanding how Brazilian filings interact with international prosecution strategies is therefore essential for foreign patent attorneys working with biotechnology inventions.
Final thoughts
We learn that in cases like Polylaminin, where academic innovation gradually evolved into a scalable therapeutic platform, stronger coordination between institutions and foreign counsel could have preserved protection in key markets. For biotechnology portfolios with long development cycles and high clinical investment, treating Brazil as an integral part of the global strategy can make the difference between a locally protected invention and a truly global asset.
The success of an invention often depends on carefully planned international patent strategies and effective prosecution management.
Foreign law firms often rely on local counsel to coordinate patent prosecution before the Brazilian Patent Office (INPI) and to ensure that Brazilian filings remain aligned with broader international IP strategies.
About the authors
Rafael Garutti and Erick Cancella work on international intellectual property matters involving Brazil, with particular focus on biotechnology patents, patent prosecution and cross-border IP coordination.